The Alzheimer’s Association International Conference (AAIC) 2025 presented the latest research on Alzheimer disease (AD) and dementia, including updates on clinical trials, preclinical drug development, and clinical management. In this article, Samuel E. Gandy, MD, PhD, provides his perspective on research presented at AAIC 2025 on treatment strategies for early symptomatic AD.
At the American Academy of Neurology (AAN) Annual Meeting, held from April 5 to April 9, 2025, experts presented the latest developments in Alzheimer disease (AD) and other neurologic conditions. In this article, Lawrence S. Honig, MD, PhD, professor of neurology at Columbia University Irving Medical Center, offers insights on treatment strategies for early symptomatic AD presented at the meeting.
The 24th Alzheimer’s Association International Conference (AAIC) highlighted new developments in the early treatment of Alzheimer disease (AD). Erik C.B. Johnson, MD, PhD, assistant professor in the Department of Neurology at Emory University School of Medicine, discusses the implications of these developments for the prevention of AD presented at AAIC 2024.
Multiple sclerosis (MS) remains a dynamic field with ongoing advances like anti-CD20 therapies and BTK inhibitors. Fred D. Lublin, MD, is the Saunders Family Professor of Neurology and director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at the Icahn School of Medicine at Mount Sinai in New York. In this article, Dr Lublin discusses current research in treatment strategies for adults with relapsing MS presented at ECTRIMS-ACTRIMS 2023.
The American Academy of Neurology (AAN) 2023 Annual Meeting featured presentations of research that explored new strategies for the diagnosis and treatment of multiple sclerosis (MS). In this article, Dean M. Wingerchuk, MD, director of the Mayo Clinic Division of Multiple Sclerosis and Autoimmune Neurology in Scottsdale, Arizona, discusses advancements in the treatment of MS.
The American Academy of Neurology hosted its 74th annual meeting in Seattle, Washington. Michael S. Okun, MD, shares his key takeaways from the plethora of sessions discussing advancements in the management of “off” episodes for patients with Parkinson disease. New drug delivery systems and formulations for carbidopa/levodopa (CD/LD) are among the exciting changes from the 2022 AAN meeting.
Jacqueline T. Bernard, MD, FAAN, neurologist, associate professor of neurology, quality chief, and clinical vice-chair in the School of Medicine at Oregon Health & Science University, Portland, discusses promising research in multiple sclerosis and neuromyelitis optica spectrum disorders that was presented at the American Academy of Neurology 2021 Virtual Annual Meeting.
Please login or register first to view this content.